Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …

Carcinogenesis is accompanied by widespread DNA methylation changes within the cell.
These changes are characterized by a globally hypomethylated genome with focal …

Early detection has the potential to reduce cancer mortality, but an effective screening test
must demonstrate asymptomatic cancer detection years before conventional diagnosis in a …

In recent years, the rapid development of next-generation sequencing (NGS) technologies
has led to a significant reduction in sequencing cost with improved accuracy. In the area of …

Liquid biopsies, in particular, analysis of cell-free DNA (cfDNA), have emerged as a
promising noninvasive diagnostic approach in oncology. Abnormal distribution of DNA …

An effective blood-based method for the diagnosis and prognosis of hepatocellular
carcinoma (HCC) has not yet been developed. Circulating tumour DNA (ctDNA) carrying …

Circulating tumor DNA (ctDNA) has emerged as a useful diagnostic and prognostic
biomarker in many cancers. Here, we conducted a study to investigate the potential use of …

The past 10 years have seen great advances in our ability to manipulate cell fate, including
the induction of pluripotency in vitro to generate induced pluripotent stem cells (iPSCs). This …

The ability to identify a specific cancer using minimally invasive biopsy holds great promise
for improving the diagnosis, treatment selection, and prediction of prognosis in cancer …

For over 60 years, the synthetic production of new DNA sequences has helped researchers
understand and engineer biology. Here we summarize methods and caveats for the de novo …